VIMTA LABS LTD.-$

Vimta Labs Limited announced its unaudited financial results for the first quarter ended June 30, 2026. Total income for Q1 FY27 stood at ₹1,129 million, marking a 13.7% year-on-year increase. EBITDA margins were reported at 36.4%, and PAT margins at 18.6%. The company highlighted strong performance in Pharmaceutical Research and Testing Services, while the Food Testing division navigated global uncertainties through domestic market penetration. Vimta Labs also successfully completed a regulatory audit from Ukraine and commenced operations in Biologics contract research and development services (CRADS). The Managing Director expressed optimism about future prospects.

Vimta Labs Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The results were reviewed by the Audit Committee and approved by the Board of Directors. The company has complied with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Indian Accounting Standard 34 for interim financial reporting. The independent auditor's review report indicates no material misstatements.

Vimta Labs opened FY27 with a steady, in-line quarter rather than an acceleration. Standalone revenue from operations rose 11.8% YoY to ₹109.07 Cr and net profit rose 11.4% YoY to ₹21.04 Cr (EPS ₹4.71 vs ₹4.25), with net margin edging up to 19.3% from 19.0% a year ago. Sequentially the print was essentially flat — revenue -0.2% and PAT -0.3% against a strong Q4 (₹109.25 Cr / ₹21.11 Cr) — which is a soft handoff given Q4 is typically the peak quarter. The company runs a single segment (Contract Research & Testing) and reported no exceptional items this quarter, so reported and underlying growth are the same ~11%. The number sits below both external and internal bars. Analysts model 15-20% PAT growth for FY27; the ~11% Q1 print trails that. It also runs well short of management's own Q4-concall stretch target of 20-25% revenue CAGR, so on the growth headline this reads as a miss, even as the margin promise held — operating margin at ~34.2% is broadly in line with the year-ago 34.5% and within the 1-2% correction management had cautioned on for cost pressures. The bottom line was helped by a more-than-doubling of other income (₹1.75→₹3.81 Cr) and a lower ESOP charge (₹0.85 Cr vs ₹1.52 Cr), while other expenses rose ~14% YoY — so the profit quality is a touch softer than the headline PAT growth implies. Strategically the watched item is biologics: management had guided commercialization of its ~₹50 Cr biologics CRDS build-out from Q1 FY27, with the explicit caveat that FY27 is about credibility and customer traction, not revenue. This quarter shows no visible biologics contribution, consistent with that framing. Concurrent board actions were routine — a fresh grant of 40,500 ESOPs on July 20 and the earlier ₹2 FY26 dividend — none material to the print. The quarter neither confirms nor contradicts the bullish Q4 tone on demand; it simply lands at a slower double-digit pace than the 20%+ ambition set on that call.

Vimta Labs Ltd has announced that its Board of Directors will convene on July 20, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. In line with SEBI regulations, the company has also implemented a trading window closure from July 1, 2026, which will remain shut until 48 hours after the announcement of these financial results. This intimation is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and a copy is available on the company's website.

Vimta Labs Ltd has announced the payment of a dividend of ₹2 per equity share for the financial year 2025-26. This dividend was approved by the shareholders at the Annual General Meeting and has been paid to eligible shareholders on July 4, 2026. This action follows their earlier communication regarding the dividend recommendation.

Vimta Labs Ltd has announced the closure of its trading window for the first quarter of the financial year 2026-27. This closure is a standard corporate governance practice to prevent insider trading during periods when unpublished price-sensitive information may be available. The exact dates for the closure and reopening of the trading window are typically communicated separately, but this announcement signals the approach of the quarterly results announcement period.

Vimta Labs Ltd. announced its 36th Annual General Meeting (AGM) scheduled for Thursday, June 25, 2026, at 10:00 AM IST. The meeting will be held via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The notice and annual report for FY 2025-26 are available on the company's website. Agenda includes adopting financial statements, declaring a dividend of ₹2 per share, and director reappointment. Special business includes ratification of cost auditor remuneration and reappointment of Dr. S P Vasireddi as Executive Chairman.

Vimta Labs Ltd. has re-appointed Dr. S. P. Vasireddi (DIN 00242288) as Executive Chairman, based on the recommendations of the Nomination and Remuneration Committee and the approval of the Audit Committee. The re-appointment, approved by the Board of Directors on May 6, 2026, is subject to shareholder approval at the upcoming Annual General Meeting. His term will be for five years, from July 1, 2026, to June 30, 2031. Dr. Vasireddi's profile and experience are detailed in Annexure I, as per SEBI circulars dated July 13, 2023, and November 11, 2024.

Vimta Labs Ltd has announced that its Board of Directors, in a meeting held on May 6, 2026, recommended a dividend of ₹2 per share on equity shares with a face value of ₹2 each for the financial year 2025-26. This dividend is subject to the approval of shareholders at the upcoming Annual General Meeting. The record date for the dividend payment, pending shareholder approval, is set for June 18, 2026, and the payment will be made on or before July 8, 2026.

Vimta Labs Ltd announced its Q4 and FY26 financial results. FY26 revenue reached ₹4,163 Mn, a 19.5% increase YoY. EBITDA margins stood at 35.8%, and PAT margin at 18.6%. Q4 FY26 revenue was ₹1,120 Mn, up 11.5% YoY. The company highlighted strong performance in its Pharma and Food divisions, driven by sustained demand and customer confidence. Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, with the transfer completed on October 11, 2024.